Pediatric ENT emergencies pose unique risks because small anatomic airways can make minor pathology life-threatening in minutes. The WHO pediatric emergency care framework underscores the urgency of ...

Abbott is getting into cancer testing with its $21 billion acquisition Exact Sciences, the maker of the game-changing colorectal cancer test Cologuard. Abbott markets well-known diagnostics for ...

CARLSBAD, Calif.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, has received approval from the U.S. Food and Drug Administration (FDA) for its Ion Torrent™ Oncomine™ ...

North suburban-based Abbott Laboratories announced a $21 billion deal Thursday morning to acquire Exact Sciences, the maker of Cologuard — its largest acquisition in a decade. The deal will allow ...

The pending $23 billion sale of Madison-based Exact Sciences to health care giant Abbott centers on Exact Sciences' flagship product: colorectal cancer test Cologuard. Exact Sciences markets Cologuard ...

Thermo Fisher Scientific’s Oncomine Dx Target Test Receives FDA Approval as a Companion Diagnostic to Identify Patients Eligible for Newest Targeted Therapy for Non-Small Cell Lung Cancer Test will ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. Abbott said Thursday it would buy Exact Sciences, the maker of tests ...

Exact Sciences (EXAS) soared 28% on a report that Abbott Laboratories (ABT) is nearing a possible takeover of the medical-testing company. Abbott (ABT) is discussing the terms of a deal with Exact ...

Abbott Laboratories is nearing a potential acquisition of cancer screening company Exact Sciences Corp., people familiar with the matter said, in what could be the biggest deal of the year in the ...

Just off the MacArthur Causeway, cars queue on an easily missed outlet between PortMiami and South Beach. A Ferrari pulls in behind a Bentley, which idles behind a humble BMW. A uniformed attendant ...